share_log

Independent Director Scott Schlackman Sold A Bunch Of Shares In Medifast

Independent Director Scott Schlackman Sold A Bunch Of Shares In Medifast

独立董事斯科特·施拉克曼出售了Medifast的大量股票
Simply Wall St ·  03/15 06:14

Anyone interested in Medifast, Inc. (NYSE:MED) should probably be aware that the Independent Director, Scott Schlackman, recently divested US$109k worth of shares in the company, at an average price of US$39.46 each. The eyebrow raising move amounted to a reduction of 37% in their holding.

任何对Medifast, Inc.(纽约证券交易所代码:MED)感兴趣的人都应该知道,独立董事斯科特·施拉克曼最近剥离了该公司价值10.9万美元的股份,平均每股价格为39.46美元。令人惊讶的举动使他们的持股量减少了37%。

Medifast Insider Transactions Over The Last Year

去年的Medifast内幕交易

In the last twelve months, the biggest single sale by an insider was when the insider, Constance Hallquist, sold US$415k worth of shares at a price of US$73.87 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$34.57. So it may not shed much light on insider confidence at current levels.

在过去的十二个月中,知情人最大的一次出售是知情人康斯坦斯·哈尔奎斯特以每股73.87美元的价格出售了价值41.5万美元的股票。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是是否以较低的价格进行销售。好消息是,此次大宗销售远高于当前的34.57美元。因此,在当前水平上,这可能无法为内部信心提供太多启示。

In the last twelve months insiders purchased 675.43 shares for US$55k. On the other hand they divested 8.37k shares, for US$523k. In total, Medifast insiders sold more than they bought over the last year. The average sell price was around US$62.55. It is certainly not great to see that insiders have sold shares in the company. But the selling was at much higher prices than the current share price (US$34.57), so it probably doesn't tell us a lot about the value on offer today. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

在过去的十二个月中,内部人士以5.5万美元的价格购买了675.43股股票。另一方面,他们以52.3万美元的价格剥离了8.37万股股票。去年,Medifast内部人士的总销售量超过了他们的购买量。平均售价约为62.55美元。看到内部人士出售该公司的股票肯定不是一件好事。但是此次出售的价格远高于当前的股价(34.57美元),因此它可能无法告诉我们很多有关当今股票价值的信息。你可以在下面看到过去 12 个月的内幕交易(公司和个人)的直观描述。通过点击下面的图表,你可以看到每笔内幕交易的确切细节!

insider-trading-volume
NYSE:MED Insider Trading Volume March 15th 2024
纽约证券交易所:MED 内幕交易量 2024 年 3 月 15 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你喜欢买内部人士买入而不是卖出的股票,那么你可能会喜欢这份免费的公司名单。(提示:业内人士一直在购买它们)。

Does Medifast Boast High Insider Ownership?

Medifast 是否拥有很高的内部所有权?

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Medifast insiders own 1.8% of the company, worth about US$7.0m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

许多投资者喜欢查看公司内部人士拥有多少股份。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。从我们的数据来看,Medifast内部人士似乎拥有该公司1.8%的股份,价值约700万美元。总的来说,这种所有权水平并不那么令人印象深刻,但肯定总比没有好!

What Might The Insider Transactions At Medifast Tell Us?

Medifast的内幕交易能告诉我们什么?

An insider sold Medifast shares recently, but they didn't buy any. And our longer term analysis of insider transactions didn't bring confidence, either. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 2 warning signs for Medifast (1 shouldn't be ignored!) that we believe deserve your full attention.

一位内部人士最近出售了Medifast的股票,但他们没有购买任何股票。而且,我们对内幕交易的长期分析也没有带来信心。当你考虑到大多数公司的内部所有权水平更高时,我们有点警惕。因此,我们只有在经过仔细考虑后才会购买。因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。当我们进行研究时,我们发现了 Medifast 的 2 个警告信号(1 个不容忽视!)我们认为值得你全神贯注。

Of course Medifast may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

当然,Medifast可能不是最值得购买的股票。因此,您可能希望看到这个免费的高质量公司集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发